Mode
Text Size
Log in / Sign up
N/A Completed N=252 Randomized Double-blind Supportive Care

Clinical Assessment of a HYDRAGLYDE® Regimen

Refractive errors · Myopia · Hypermetropia
Source: ClinicalTrials.gov NCT03026257 ↗
Enrolled (actual)
252
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcomePrimary: Ex Vivo Total Cholesterol Uptake at Day 30 — 0.28; 0.28; 2.17; 4.18 μg — p=<0.0001

Summary

The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for cholesterol uptake.

Outcome Measures

OutcomeResultp-value
PRIMARY
Ex Vivo Total Cholesterol Uptake at Day 30
0.28; 0.28; 2.17; 4.18; 2.07; 2.19 <0.0001 sig

Eligibility Criteria

Inclusion Criteria

  • Must sign informed consent document;
  • Vision correctable to 0.1 (LogMAR) or better in each eye at distance with habitual lenses;
  • Manifest cylinder (at screening) less than or equal to 0.75 diopter (D) in each eye and spectacle add <+0.50 D in each eye;
  • Current full-time wearer of spherical samfilcon A, comfilcon A, senofilcon C monthly or senofilcon A 2-week replacement lens within the power range of lens powers available;
  • Current user of an MPS (excluding OFPM) to care for lenses;
  • Willing to answer text messages on a daily basis during the study;
  • Willing to discontinue artificial tears during the study and rewetting drops on the days of study visits;
  • Use of digital devices (eg, smart phone, tablet, laptop or desktop computer) for 20 consecutive minutes at least twice a week and willing to continue for the duration of the study;
  • Other protocol specific inclusion criteria may apply.

Exclusion Criteria

  • Habitual lens wear in an extended wear modality (routinely sleeping in lenses overnight for 1 or more nights per week);
  • Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear;
  • History of herpetic keratitis, corneal surgery or irregular cornea;
  • Prior refractive surgery;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator;
  • Currently using or have not discontinued Restasis®, Xiidra™ and/or topical steroids within the past 7 days;
  • Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and not willing to discontinue during the study;
  • Monocular (only 1 eye with functional vision) or fit with only 1 lens;
  • Known pregnancy or lactating;
  • Other protocol specific exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03026257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search